Quoin Pharmaceuticals(QNRX) surged 20% premarket after positive feedback from the FDA regarding its Netherton syndrome drug. The FDA suggested a single Phase 3 trial may be sufficient for approval. Quoinset is confident of completing recruitment this year and could file for approval as early as 2027. CEO Michael Myers called the FDA's guidance encouraging for the company's fast-track to market.